Atlas Trials

Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone

Clinical trial NCT00968968 · TERMINATED

Trial details

NCT number
NCT00968968
Sponsor
Novartis Pharmaceuticals
Status
TERMINATED
Phase
Phase 3
Study type
INTERVENTIONAL
Cancer
Start date
2010-01-20
Primary completion
2014-02-21
Enrollment
37

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.